EUVIMEDEUVIMED entdecken
FallberichtOpen Access

DNMT3A co-mutation in an IDH1 -mutant glioblastoma

Elena I Fomchenko, E Zeynep Erson-Omay, Amy Zhao, Ranjit S Bindra, Anita Huttner, Robert K Fulbright, Jennifer Moliterno

Molecular Case Studies · 2019-08 · 5 (4) · a004119

DOI: 10.1101/mcs.a004119 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 01.08.2019. Verfasst von Elena I Fomchenko und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut 06520, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastomas are highly aggressive, infiltrative, and genetically heterogeneous primary brain tumors that arise de novo or secondarily progress over time from low-grade tumors. Along with well-established signature mutational profiles, emerging research suggests that the epigenetic tumor landscape plays an important role in gliomagenesis via transcriptional regulation, DNA methylation, and histone modifications. The pursuit of targeted therapeutic approaches, based not only on expression profiles but also on somatic mutations, is fundamental to the effort of improving survival in patients with glioblastoma. Here, we describe a missense DNMT3A p.P904S mutation in an IDH1 -mutant glioblastoma. Although never previously reported in gliomas, this mutation is predicted to be pathogenic and has been reported in several other malignancies. Our report suggests that elucidating epigenetic control is important to understanding glioblastoma biology and may likely unveil targets potentially important to glioblastoma treatment in an effort to improve survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultBiomarkers, TumorBrain NeoplasmsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3ADNA Modification MethylasesEpigenesis, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticGlioblastomaGliomaHumansIsocitrate DehydrogenaseMaleMutationMutation, MissensePromoter Regions, Genetic

Stichwörter der Autor:innen

neoplasm of the nervous system

Substanzen

Biomarkers, TumorDNMT3A protein, humanIsocitrate DehydrogenaseIDH1 protein, humanDNA Modification MethylasesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3A

Autor:innen und Institutionen

  • Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut 06520, USA.
  • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut 06520, USA.
  • Department of Pathology, Yale School of Medicine, New Haven, Connecticut 06520, USA.
  • Department of Radiology, Yale School of Medicine, New Haven, Connecticut 06520, USA.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Fomchenko, E. I., Erson-Omay, E. Z., Zhao, A., Bindra, R. S., Huttner, A., Fulbright, R. K., & Moliterno, J. (2019). DNMT3A co-mutation in an IDH1 -mutant glioblastoma. Molecular Case Studies, 5(4), a004119. https://doi.org/10.1101/mcs.a004119

Vancouver

Fomchenko EI, Erson-Omay EZ, Zhao A, Bindra RS, Huttner A, Fulbright RK, et al. DNMT3A co-mutation in an IDH1 -mutant glioblastoma. Molecular Case Studies. 2019;5(4):a004119. doi:10.1101/mcs.a004119

BibTeX
@article{Fomchenko2019,
  author = {Fomchenko, Elena I and Erson-Omay, E Zeynep and Zhao, Amy and Bindra, Ranjit S and Huttner, Anita and Fulbright, Robert K and Moliterno, Jennifer},
  title = {DNMT3A co-mutation in an IDH1 -mutant glioblastoma},
  journal = {Molecular Case Studies},
  year = {2019},
  volume = {5},
  number = {4},
  pages = {a004119},
  doi = {10.1101/mcs.a004119}
}
Kostenlos starten →